Logo

OncoBlast-Advances in GI Cancer Care: Case-Based Approaches to Modern Therapy

This OncoBlast activity uses clinical cases to explore new standards in treating gastroesophageal, colorectal, biliary, and neuroendocrine cancers. Learners will apply recent trial data to make evidence-based decisions in both curative and metastatic settings.

Course Accreditations

Course Summary

Events StartsEvents Ends
1/1/202512/31/2025

Faculty

Ronan Hsieh   (MD)

As a faculty at the University of Washington Fred Hutchinson Cancer Center, I lead many clinical and translational studies in the field of gastrointestinal oncology. I focus my research on drug development using novel trial design and cancer models such as tissue slice culture and organoids, which I collaborate with translational scientists at Fred Hutch. Fun facts - I grew up in Taiwan, so you can hear me promoting bubble tea as the best beverage in the world all the time. I like hiking and cycling, and naturally I love Seattle as my new home town in the U.S.

Disclosure

Financial relationships Yes, I have had a financial relationship with an ineligible company within the past 24 months. Financial relationships: Attribution: Self Type of financial relationship: Financial Support Ineligible company: Curio Science Topic: Honorarium Attribution: Self Type of financial relationship: Professional Services Ineligible company: Bristol Myers Squibb Topic: Advisory Board Attribution: Self Type of financial relationship: Professional Services Ineligible company: Bayer Topic: Research Support Attribution: Self Type of financial relationship: Professional Services Ineligible company: Janssen Topic: Research Support Attribution: Self Type of financial relationship: Travel Ineligible company: Medscape Attribution: Self Type of financial relationship: Travel Ineligible company: Merck

top-curriculum

    Target Audience

  • Medical oncologists
  • Radiation oncologists
  • Surgical oncologists
  • Hematology/Oncology Fellows

    Learning Objectives

    Upon successful completion of this educational activity, participants will be able to:

  • Select appropriate perioperative and systemic therapies for GI cancers based on latest evidence.
  • Integrate biomarker testing results to guide treatment decisions across GI malignancies.
  • Apply emerging standards for managing NETs and biliary cancers.